FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214807404> ?p ?o ?g. }

• W4214807404 abstract "The expression of Coiled-Coil Domain Containing 134(CCDC134) is up-regulated in different pan-cancer species. However, its prognostic value and correlation with immune infiltration in breast cancer are unclear. Therefore, we evaluated the prognostic role of CCDC134 in breast cancer and its correlation with immune invasion.We downloaded the transcription profile of CCDC134 between breast cancer and normal tissues from the Cancer Genome Atlas (TCGA). CCDC134 protein expression was assessed by the Clinical Proteomic Cancer Analysis Consortium (CPTAC) and the Human Protein Atlas. Gene set enrichment analysis (GSEA) was also used for pathway analysis. Receiver operating characteristic (ROC) curve was used to differentiate breast cancer from adjacent normal tissues. Kaplan-Meier method was used to evaluate the effect of CCDC134 on survival rate. The protein-protein interaction (PPI) network is built from STRING. Function expansion analysis is performed using the ClusterProfiler package. Through tumor Immune Estimation Resource (TIMER) and tumor Immune System Interaction database (TISIDB) to determine the relationship between CCDC134 expression level and immune infiltration. CTD database is used to predict drugs that inhibit CCDC134 and PubChem database is used to determine the molecular structure of identified drugs.The expression of CCDC134 in breast cancer tissues was significantly higher than that of CCDC134 mRNA expression in adjacent normal tissues. ROC curve analysis showed that the AUC value of CCDC134 was 0.663. Kaplan-meier survival analysis showed that patients with high CCDC134 had a lower prognosis (57.27 months vs 36.96 months, P = 2.0E-6). Correlation analysis showed that CCDC134 mRNA expression was associated with tumor purity immune invasion. In addition, CTD database analysis identified abrine, Benzo (A) Pyrene, bisphenol A, Soman, Sunitinib, Tetrachloroethylene, Valproic Acid as seven targeted therapy drugs that may be effective treatments for seven targeted therapeutics. It may be an effective treatment for inhibiting CCDC134.In breast cancer, upregulated CCDC134 is significantly associated with lower survival and immune infiltrates invasion. Our study suggests that CCDC134 can serve as a biomarker of poor prognosis and a potential immunotherapy target in breast cancer. Seven drugs with significant potential to inhibit CCDC134 were identified." @default.
• W4214807404 created "2022-03-05" @default.
• W4214807404 creator A5008199157 @default.
• W4214807404 creator A5015197422 @default.
• W4214807404 creator A5041409033 @default.
• W4214807404 creator A5041470064 @default.
• W4214807404 creator A5042576995 @default.
• W4214807404 creator A5058755543 @default.
• W4214807404 creator A5062823224 @default.
• W4214807404 creator A5070653805 @default.
• W4214807404 creator A5085295350 @default.
• W4214807404 date "2022-03-03" @default.
• W4214807404 modified "2023-09-26" @default.
• W4214807404 title "CCDC134 as a Prognostic-Related Biomarker in Breast Cancer Correlating With Immune Infiltrates" @default.
• W4214807404 cites W1993733793 @default.
• W4214807404 cites W1997167556 @default.
• W4214807404 cites W2006617902 @default.
• W4214807404 cites W2012034410 @default.
• W4214807404 cites W2020830322 @default.
• W4214807404 cites W2035618305 @default.
• W4214807404 cites W2044702943 @default.
• W4214807404 cites W2057545775 @default.
• W4214807404 cites W2082987222 @default.
• W4214807404 cites W2106787323 @default.
• W4214807404 cites W2118299978 @default.
• W4214807404 cites W2118728607 @default.
• W4214807404 cites W2143592376 @default.
• W4214807404 cites W2329659234 @default.
• W4214807404 cites W2329674354 @default.
• W4214807404 cites W2736730167 @default.
• W4214807404 cites W2765224588 @default.
• W4214807404 cites W2767019634 @default.
• W4214807404 cites W2795989238 @default.
• W4214807404 cites W2889646458 @default.
• W4214807404 cites W2917837889 @default.
• W4214807404 cites W2937441321 @default.
• W4214807404 cites W3005045669 @default.
• W4214807404 cites W3007573310 @default.
• W4214807404 cites W3011584065 @default.
• W4214807404 cites W3015079957 @default.
• W4214807404 cites W3026381352 @default.
• W4214807404 cites W3047329278 @default.
• W4214807404 cites W3088977911 @default.
• W4214807404 cites W3120446419 @default.
• W4214807404 cites W3128646645 @default.
• W4214807404 cites W3128836016 @default.
• W4214807404 cites W3144861024 @default.
• W4214807404 cites W3159209990 @default.
• W4214807404 cites W3175109719 @default.
• W4214807404 cites W3176004707 @default.
• W4214807404 cites W3195716625 @default.
• W4214807404 cites W3198423385 @default.
• W4214807404 cites W3208025421 @default.
• W4214807404 doi "https://doi.org/10.3389/fonc.2022.858487" @default.
• W4214807404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35311121" @default.
• W4214807404 hasPublicationYear "2022" @default.
• W4214807404 type Work @default.
• W4214807404 citedByCount "2" @default.
• W4214807404 countsByYear W42148074042022 @default.
• W4214807404 crossrefType "journal-article" @default.
• W4214807404 hasAuthorship W4214807404A5008199157 @default.
• W4214807404 hasAuthorship W4214807404A5015197422 @default.
• W4214807404 hasAuthorship W4214807404A5041409033 @default.
• W4214807404 hasAuthorship W4214807404A5041470064 @default.
• W4214807404 hasAuthorship W4214807404A5042576995 @default.
• W4214807404 hasAuthorship W4214807404A5058755543 @default.
• W4214807404 hasAuthorship W4214807404A5062823224 @default.
• W4214807404 hasAuthorship W4214807404A5070653805 @default.
• W4214807404 hasAuthorship W4214807404A5085295350 @default.
• W4214807404 hasBestOaLocation W42148074041 @default.
• W4214807404 hasConcept C104317684 @default.
• W4214807404 hasConcept C10515644 @default.
• W4214807404 hasConcept C121608353 @default.
• W4214807404 hasConcept C126322002 @default.
• W4214807404 hasConcept C143998085 @default.
• W4214807404 hasConcept C158163496 @default.
• W4214807404 hasConcept C203014093 @default.
• W4214807404 hasConcept C502942594 @default.
• W4214807404 hasConcept C530470458 @default.
• W4214807404 hasConcept C55493867 @default.
• W4214807404 hasConcept C58471807 @default.
• W4214807404 hasConcept C6856738 @default.
• W4214807404 hasConcept C71924100 @default.
• W4214807404 hasConcept C86803240 @default.
• W4214807404 hasConcept C8891405 @default.
• W4214807404 hasConceptScore W4214807404C104317684 @default.
• W4214807404 hasConceptScore W4214807404C10515644 @default.
• W4214807404 hasConceptScore W4214807404C121608353 @default.
• W4214807404 hasConceptScore W4214807404C126322002 @default.
• W4214807404 hasConceptScore W4214807404C143998085 @default.
• W4214807404 hasConceptScore W4214807404C158163496 @default.
• W4214807404 hasConceptScore W4214807404C203014093 @default.
• W4214807404 hasConceptScore W4214807404C502942594 @default.
• W4214807404 hasConceptScore W4214807404C530470458 @default.
• W4214807404 hasConceptScore W4214807404C55493867 @default.
• W4214807404 hasConceptScore W4214807404C58471807 @default.
• W4214807404 hasConceptScore W4214807404C6856738 @default.
• W4214807404 hasConceptScore W4214807404C71924100 @default.
• W4214807404 hasConceptScore W4214807404C86803240 @default.
• W4214807404 hasConceptScore W4214807404C8891405 @default.

• next